MPEO-PLA nanoparticles: Effect of MPEO content on some of their surface properties

Journal of Biomedical Materials Research

Volumn 44, Issue 1, 1999, Pages 109-115

  Zambaux, M F ^a   Bonneaux, F ^a   Gref, R ^b   Dellacherie, E ^b   Vigneron, C ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b LAB DE CHIM PHYS MACROMOLECULAIRE   (France)

Author keywords

Complement consumption; Freeze drying; Monomethoxypoly(ethylene oxyde) poly(lactic acid); Nanoparticles; Surface density

Indexed keywords

CELLS; COMPOSITION EFFECTS; DENSITY (SPECIFIC GRAVITY); MOLECULAR WEIGHT; NANOSTRUCTURED MATERIALS; PARTICLES (PARTICULATE MATTER); POLYESTERS; POLYETHYLENE OXIDES; POLYMER BLENDS; SUGAR (SUCROSE); SURFACE PROPERTIES;

MONOMETHOXYPOLYETHYLENE OXIDE; POLYLACTIC ACID;

BIOMATERIALS;

BIOMATERIAL; NANOPARTICLE; POLYLACTIC ACID;

ARTICLE; COMPLEMENT ACTIVATION; COVALENT BOND; CRYSTALLIZATION; FREEZE DRYING; HYDROLYSIS; MONONUCLEAR CELL; PARTICULATE MATTER; PHAGOCYTOSIS; SURFACE PROPERTY;

BIOCOMPATIBLE MATERIALS; COMPLEMENT SYSTEM PROTEINS; FREEZE DRYING; HUMANS; LACTIC ACID; PHAGOCYTES; PHAGOCYTOSIS; POLYETHYLENE GLYCOLS; POLYMERS; SURFACE PROPERTIES;

EID: 0031726555     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4636(199901)44:1<109::AID-JBM12>3.0.CO;2-C     Document Type: Article

References (25)

1. Mauduit J, Vert M. Les polymères à base d'acides lactiques et glycoliques et la délivrance contrôlée de principes actifs. STP Pharm Sci 1993;3(3):197-212.
2. Verrechia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M. Nonstealth [poly(lactic acid:albumin)] and stealth [poly(lactic acid-polyethylene glycol)] nanoparticles as injectable drug carriers. J Controlled Rel 1995;36: 49-61.
3. Fernandez-Urrusuno R, Fattal E, Rodrigues Jr. JM, Féger J, Bedossa P, Couvreur P. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J Biomed Mater Res 1996;31:401-408.
4. Alléman E, Gurny R, Doelker E. Drug-loaded nanoparticles - Preparation methods and drug targeting issues. Eur J Pharm Biopharm 1993;39:171-191.
5. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Del Rev 1995;17:31-48.
6. Dunn SE, Coombes AGA, Garnett MC, Davis SS, Davis MC, Ilium L. In vitro cell interaction and in vivo distribution of poly(lactide-co-glycolide) nanosphere surface modified by poloxamer and poloxamine copolymers. J Controlled Rel 1997;44: 65-76.
7. Müller RH, Wallis KH. Surface modification of iv injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int J Pharm 1993;89:25-31.
8. Leroux JC, Gravel P, Balant L, Volet B, Anner BM, Allémann E, Doelker E, Gurny R. Internalization of poly(D,L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles. J Biomed Mater Res 1994;28:471-481.
9. Allémann E, Brasseur N, Benrezzak O, Rousseau J, Kudrevich SV, Boyle RW, Leroux JC, Gurny R, Van Lier JE. PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours. J Pharm Pharmacol 1995;47:382-387.
10. Bazile D, Michalon JP, Prud'homme C, Spenlehauer G, Veillard M. French. Patent 08041, 1991.
11. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994;263:1600-1603.
12. Jeon SI, Lee JH, Andrade JD, de Gennes PG. Protein-surface interactions in the presence of polyethylene oxyde. J Colloid Interface Sci 1991;142(1):149-166.
13. Bernard J, Lévy JP, Varet B, Clauvel JP, Rain JD, Sultan Y. Hématologie, 8th ed. Masson Editors; 1996.
14. Vittaz M, Bazile D, Spenlehauer G, Verrecchia T, Veillard M, Puisieux F, Labarre D. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 1996;17:1575-1581.
15. Bouillot P, Gref R, Petit A, Dellacherie E. Protein encapsulation in biodegradable amphiphilic microspheres. I. Polymer synthesis and characterization and microspheres elaboration. J Appl Polym Sci 1998;68(10):1695-1702.
16. Zambaux MF, Bonneaux F, Gref R, Alonso MJ, Maincent P, Dellacherie E, Labrude P, Vigneron C. Influence of experimental parameters on the characteristics of PLA nanoparticles prepared by a double emulsion method. J Controlled Rel 1998;50: 31-40.
17. Müller RH. Colloidal carriers for controlled drug delivery and targeting. Boca Raton, Florida: CRC Press; 1991. p 45-56.
18. Sims GEC, Snape TJ. A method for the estimation of polyethylene glycol in plasma protein fractions. Anal Biochem 1980; 107:60-63.
19. Paris-Hamelin A, Devillechabrolle A. Travaux pratiques du C.E.S. d'immunologie générale, 4th ed. Paris: Librairie Le François; 1977. p 68-76.
20. Vemuri S, Yu CD, Degroot JS, Wangsatornthnakum V, Venkataram S. Effect of sugars on freeze-thaw and lyophilization of liposomes. Drug Dev Indus Pharm 1991;17:327-348.
21. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res 1997;14(8):969-975.
22. Osterberg T, Fatouros A, Mikaelsson M. Development of a freeze-dried albumin-free formulation of recombinant factor VIII SQ. Pharm Res 1997;14(7):892-898.
23. De Jaeghere F, Alléman E, Leroux JC, Stevels W, Dijkstra PJ, Doelker E, Gurny R. PLA-PEG nanoparticles: Preparation and cell interaction studies. Proc Int Symp Control Rel Bioact Mater 1997;24, Stockholm.
24. Izutsu K, Yoshioka S, Kojima S, Randolph TW, Carpenter JF. Effects of sugars and polymers on crystallization of poly(ethylene glycol) in frozen solutions: Phase separation between incompatible polymers. Pharm Res 1996;13(9):1393-1400.
25. Gombotz WR, Guanghui W, Horbett TA, Hoffman AS. Protein adsorption to poly(ethylene oxyde) surfaces. J Biomed Mater Res 1991;25:1547-1562.